ATLANTA, April 26, 2012 /PRNewswire/ -- Insights into the effects of Neupro(®) (rotigotine transdermal system) on common non-motor symptoms of Parkinson's disease (PD) were

ATLANTA, April 25, 2012 /PRNewswire/ -- New post-hoc analyses of pivotal clinical trials of Neupro® (rotigotine transdermal system) in patients with Restless Legs Syndrome (RLS)/Willis

ATLANTA, April 20, 2012 /PRNewswire/ -- Data examining the effect of Neupro® (rotigotine transdermal system) in both Parkinson's disease and Restless Legs Syndrome (RLS) will

regulated information--UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro® (Rotigotine Transdermal System) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). Neupro® was previously approved by the FDA for the signs and symptoms of early stage idiopathic PD. Neupro®

NESS ZIONA, Israel, November 9, 2011 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ], Ltd.